Zai Lab to Announce Full-Year Financial Results and Corporate Updates on March 1, 2022 Read more about Zai Lab to Announce Full-Year Financial Results and Corporate Updates on March 1, 2022
Zai Lab Announces Upcoming Presentation at February Investor Conference Read more about Zai Lab Announces Upcoming Presentation at February Investor Conference
Zai Lab Announces First Patient Treated in Greater China in PANOVA-3 Phase 3 Pivotal Trial of Tumor Treating Fields in Pancreatic Cancer Read more about Zai Lab Announces First Patient Treated in Greater China in PANOVA-3 Phase 3 Pivotal Trial of Tumor Treating Fields in Pancreatic Cancer
Zai Lab Announces NDA Acceptance of Margetuximab for Patients with Pretreated Metastatic HER2-Positive Breast Cancer in China by the NMPA Read more about Zai Lab Announces NDA Acceptance of Margetuximab for Patients with Pretreated Metastatic HER2-Positive Breast Cancer in China by the NMPA
Zai Lab Announces Upcoming Presentations at January Investor Conferences Read more about Zai Lab Announces Upcoming Presentations at January Investor Conferences
Zai Lab Announces Promotion of Harald Reinhart, M.D. to President and Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases Read more about Zai Lab Announces Promotion of Harald Reinhart, M.D. to President and Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases
Zai Lab Partner argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis Read more about Zai Lab Partner argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis